Alterations of lipid metabolism in Wilson disease

Jessica Seessle¹, Annina Gohdes¹, Daniel Nils Gotthardt¹, Jan Pfeiffenberger¹, Nicola Eckert¹, Wolfgang Stremmel¹, Ulrike Reuner²† and Karl Heinz Weiss¹*†

Abstract

Introduction: Wilson disease (WD) is an inherited disorder of human copper metabolism, characterised by accumulation of copper predominantly in the liver and brain, leading to severe hepatic and neurological disease. Interesting findings in animal models of WD (Atp7b⁻⁻ and LEC rats) showed altered lipid metabolism with a decrease in the amount of triglycerides and cholesterol in the serum. However, serum lipid profile has not been investigated in large human WD patient cohorts to date.

Patients and Methods: This cohort study involved 251 patients examined at the Heidelberg and Dresden (Germany) University Hospitals. Patients were analysed on routine follow-up examinations for serum lipid profile, including triglycerides, cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL). Data on these parameters at time of diagnosis were retrieved by chart review where available. For statistical testing, patients were subgrouped by sex, manifestation (hepatic, neurological, mixed and asymptomatic) and treatment (D-penicillamine, trientine, zinc or combination).

Results: A significant difference in total serum cholesterol was found in patients with hepatic symptoms, which diminished under therapy. No alterations were observed for HDL, LDL and triglycerides.

Conclusion: Contradictory to previous reports using WD animal models (Atp7b⁻⁻ and LEC rats), the most obvious alteration in our cohort was a lower serum cholesterol level in hepatic-affected patients, which might be related to liver injury. Our data suggested unimpaired cholesterol metabolism in Wilson disease under therapy, independent of the applied medical treatment.

Keywords: Wilson Disease, lipids, cholesterol, triglycerides, liver disease

Background

Wilson disease (WD) is an autosomal recessive inherited disorder of copper metabolism caused by mutations of the hepatic copper transporting ATPase ATP7B, which facilitates biliary copper excretion. Thus ATP7B dysfunction leads to toxic copper accumulation in the liver and other tissues, most notably the central nervous system [1,2]. The genetic background of the disease is highly variable with more than 300 ATP7B mutations known so far [3-5]. Liver injury is the most common manifestation of Wilson disease and it ranges from steatosis hepatis to irreversible liver cirrhosis and fulminant liver failure [6,7] with a variable age at onset [8]. The liver is not only responsible for maintenance of copper homoeostasis but plays a central role in lipid transport and metabolism. Thus liver disease can be associated with profound and characteristic changes in lipoprotein composition, metabolism and transport [9]. However, alterations of lipid metabolism in humans with copper overload disease have not been investigated in larger cohorts so far.

Here, some data are available for rodent models of WD, the Atp7b⁻⁻ mouse and the LEC rat. Atp7b knockout mice exhibit down-regulated lipid metabolism [10]. A significant decrease in the amount of triglycerides and cholesterol was detected, whereas LDL cholesterol remained unchanged [10]. Very low density lipoprotein (VLDL) fraction was the most affected, showing a 3.6-fold reduction in cholesterol concentration. Analysis of liver tissue revealed that cholesterol was indeed markedly decreased [10]. In contrast, Levy et al. showed an increased content of triglycerides, free cholesterol and

* Correspondence: Karl-Heinz_Weiss@med.uni-heidelberg.de
† Contributed equally
¹Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany
Full list of author information is available at the end of the article

© 2011 Seessle et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
cholesteryl ester in the liver of LEC rats. This steatosis was associated with hypotriglyceridemia, hypercholesterolemia and abnormalities in both circulating lipoprotein composition and size [11]. In both animal models of Atp7b-/- mice and LEC rats, there is a significant effect of accumulated copper on hepatic HMG-CoA reductase (the rate limiting enzyme in de novo cholesterol biosynthesis). HMG-CoA reductase mRNA levels were most significantly down-regulated in Atp7b-/- mice [10] while the activity of the enzyme was decreased in LEC rats [11].

Several other animal studies support the idea that lipid and copper metabolism are linked. For example, copper deficient rats showed elevated total cholesterol and triglyceride plasma levels and a significant decrease in hepatic total cholesterol [12]. HMG-CoA reductase was elevated two-fold with copper deficiency [12,13]. In male Wistar rats, Galhardi et al. showed reduced cholesterol and triglycerides, total cholesterol and LDL in the serum after dietary copper supplementation. However, there was no significant change in final body weight and high-density lipoprotein [13,14].

There are limited data regarding Wilson disease and the alteration of lipid metabolism in humans. Brewer et al. demonstrated in eleven female and thirteen male WD patients that zinc treatment reduced cholesterol levels by about 10% in both sexes and reduced HDL cholesterol level by about 20% in male patients [15]. Rodo et al. investigated 45 WD individuals treated with D-pencillamine or zinc sulphate and demonstrated significantly lower levels of cholesterol, LDL cholesterol and Vitamin E compared with untreated healthy controls. No differences were seen in triglyceride levels between both groups [16].

These findings were in line with other smaller series in healthy male individuals that evaluated the role of zinc in lipid reducing therapy [17-19]. Black et al. examined the effect of oral zinc supplementation for twelve weeks in thirty one healthy men (9 subjects in the placebo group, 13 in the 50mg Zn/d group and 9 in the 75mg Zn/d group) in a double blinded study [19]. No changes in total serum cholesterol, LDL, VLDL and triglycerides were observed. Hooper et al. showed a 25% decrease below baseline values of HDL in 12 healthy men after zinc supplementation [17]. Total cholesterol, triglycerides and LDL cholesterol levels did not change. Similar data were revealed by Chandra in 11 healthy men: HDL concentration decreased significantly and LDL increased slightly after ingestion of elemental zinc [18]. The mechanism of these effects of zinc on cholesterol metabolism is currently unclear. The aim of the current study was to assess lipid metabolism parameters in patients with Wilson disease at initial presentation and in course under medical therapy.

Results

Findings at initial presentation

In untreated Wilson disease, median serum cholesterol and triglycerides presented within the normal range. A comparison between male and female patients showed no significant differences concerning serum lipids (Table 1).

For further analysis, patients were subgrouped by presentation (neurologic, hepatic, mixed and asymptomatic). As expected, patients with hepatic manifestation showed higher levels of liver function tests namely alanine aminotransferase (ALT) and aspartate aminotransferase (AST), bilirubin and lower levels of serum albumin. Total cholesterol was lower in patients with hepatic symptoms (Figure 1) while no alterations in the other analysed parameters of lipid metabolism were noted (Table 2).

Course under medical treatment

Under at least 2 years of therapy, the differences within LFT’s (ALT, AST) diminished, reflecting the hepatic response to medical treatment. With improvement of liver function, parameters of lipid metabolism - in particular cholesterol levels - were comparable between patients, independent of initial presentation (Table 3). Moreover, it was noticeable that lipoprotein a, an independent risk factor for atherosclerosis, was significantly decreased in those individuals with hepatic and mixed presentation.

To evaluate the influence of different treatment regimens, data for patients under therapy were analysed by treatment (Table 4). For cholesterol and serum lipids, no statistically significant differences were observed between the groups. Under zinc and combination treatment, significantly higher levels of lipase and amylase, known side effects of the medication, were observed.

Discussion

The liver is a central organ in lipid transport and metabolism. It is well known that liver diseases are associated with profound and characteristic changes in lipoprotein composition and metabolism [9]. Only limited data are currently available on the detailed lipoprotein alterations in Wilson disease. The aim of the current study was to investigate alterations in lipid metabolism parameters in WD patients.

The study examined 251 Wilson disease patients. Our expectation with regard to animal models was to show altered parameters of lipid metabolism. Despite the fact that differences in VLDL were a major finding in the rodent studies [10] we focused on the lipid parameters assessed in clinical routine to follow WD patients. This represents a limitation of our study.

While Atp7b knockout mice showed down-regulated lipid metabolism with a significant decrease in the amount of triglycerides and cholesterol [11,13], in our
Table 1 A comparison between treatment naive male and female patients showed no significant differences concerning serum lipids

| Parameter | n | Limits of normal | Total | Male | Female | p-value |
|-----------|---|------------------|-------|------|--------|---------|
| ALT       | m:f | 35 U/l | -50 U/l | 62.3 (7-3743) | 95 (7-3743) | 54 (7-472) | 0.032 |
| AST       | m:f | 35 U/l | -50 U/l | 51.9 (6-2106) | 52 (6-2106) | 50 (13-323) | 0.485 |
| Bilirubin | m:f | < 1,0 mg/dl | | 0.9 (0.1-39) | 0.9 (0.2-23) | 0.9 (0.1-39) | 0.974 |
| Albumin   | m:f | 30-50 g/l | | 43 (23-57) | 43.9 (25-55) | 42.6 (23-57) | 0.179 |
| TG        | m:f | < 150 mg/dl | | 114 (33-888) | 149.5 (59-313) | 106.5 (33-888) | 0.061 |
| Cholesterol | m:f | < 200 mg/dl | | 175.5 (66-319) | 186 (93-319) | 170 (66-294) | 0.436 |
| HDL       | m:f | >50 mg/dl m: >40 mg/dl | | 56.5 (42-77) | 53 (42-67) | 57 (48-77) | 0.179 |
| LDL       | m:f | < 160 mg/dl | | 96 (63-218) | 97 (63-218) | 95 (63-166) | 0.935 |
| BMI       | m:f | 18.5-25 kg/m² | | 22.1 (14.8-30.8) | 22.9 (15.3-27.7) | 21.2 (14.8-30.8) | 0.877 |

No differences were demonstrated between both sexes in the lipid metabolism parameters.

Figure 1 Serum cholesterol subgrouped by presentation at initial presentation (n = 70). Median total serum cholesterol was reduced in hepatic patients (p = 0.004).
human cohort median serum cholesterol and triglycerides presented within the normal range. A lower median cholesterol was only evident in the subgroup of patients with hepatic symptoms. Whether this finding is a specific effect of the copper overload or just an epiphenomenon of liver injury remains open, as previous studies observed a clear trend towards low levels of total cholesterol in patients chronic liver disease [9]. All other analysed parameters of lipid metabolism were inconspicuous even in the hepatic patients. In further course under therapy the finding of lower cholesterol in patients with hepatic presentation was no longer evident. After two years of treatment the analyzed lipid metabolism parameters were comparable between patients, independent of the initial presentation.

To evaluate the influence of different treatment regimes, data were also analysed by treatment. For cholesterol and serum lipids, no statistically significant

Table 2 Baseline parameters of treatment naive patients subgrouped by different manifestation revealed a significant decrease in cholesterol in hepatic patients

| Parameter   | Limits of normal | Hepatic | Neurological | Mixed | Asymptomatic | p-value |
|-------------|------------------|---------|--------------|-------|--------------|---------|
| ALT         | f: -35 U/l; m: -50 U/l | 101.9 (7-3743) | 22 (10-140) | 28.2 (17-272) | 20 (7-168) | >0.001 |
| AST         | f: -35 U/l; m: -50 U/l | 76.9 (13-2106) | 21.2 (6-58) | 32 (19-108) | 26.4 (11-102) | >0.001 |
| Bilirubin   | f: < 1.0 mg/dl; m: < 150 mg/dl | 1.1 (0-2.39) | 0.9 (1-6) | 0.6 (2.14) | 0.5 (0-2.9) | 0.009 |
| Albumin     | 30-50 g/l | 41 (23-55) | 45.2 (38-52) | 43 (35-57) | 46.3 (35-52) | 0.001 |
| TG          | f: < 150 mg/dl; m: < 160 mg/dl | 110 (33-888) | 120 (63-200) | 124 (40-249) | 60 (59-100) | 0.300 |
| Cholesterol | f: < 200 mg/dl; m: < 160 mg/dl | 158 (66-319) | 194 (123-243) | 186 (145-244) | 195 (173-294) | 0.004 |
| HDL         | >50 mg/dl | 57 (42-76) | 53 (48-77) | 60 (56-62) | - | 0.923 |
| LDL         | < 160 mg/dl | 96 (63-218) | 161 (156-166) | 88 (81-95) | - | 0.207 |
| BMI         | 18.5-25 kg/m² | 20.6 (14-24.5) | 26.2 (20-30.8) | 23.1 (14-28.6) | 19.7 (19-21.7) | 0.126 |

Median serum cholesterol and triglycerides presented within normal range.

Table 3 Parameters of lipid metabolism of Wilson disease patients under therapy

| Parameter   | Limits of normal | Hepatic | Neurological | Mixed | Asymptomatic | p-value |
|-------------|------------------|---------|--------------|-------|--------------|---------|
| ALT         | f: -35 U/l; m: -50 U/l | 41 (10-3743) | 25 (11-70) | 30 (13-90) | 24.5 (8-70) | <0.001 |
| AST         | f: -35 U/l; m: -50 U/l | 29 (12-2106) | 23 (10-102) | 27 (12-79) | 20 (11-77) | <0.001 |
| Bilirubin   | f: < 1.0 mg/dl | 0.7 (0-2.39) | 0.6 (0-2.7) | 0.7 (0-4.5) | 0.6 (0-3.19) | 0.001 |
| Albumin     | 30-50 g/l | 44 (21-55) | 44.4 (28-56) | 44 (30-73) | 45.6 (37-54) | 0.277 |
| TG          | < 150 mg/dl | 100 (28-888) | 95 (29-438) | 106.5 (12-221) | 93 (29-286) | 0.588 |
| Cholesterol | f: < 200 mg/dl | 179.5 (90-319) | 182 (120-365) | 183 (113-273) | 188.5 (103-265) | 0.780 |
| HDL         | >50 mg/dl | 55 (27-113) | 53 (32-103) | 57.5 (40-81) | 57 (36-84) | 0.588 |
| LDL         | < 160 mg/dl | 108 (43-218) | 96 (63-229) | 98.5 (63-159) | 113.5 (74-156) | 0.781 |
| Lp(a)       | < 25 mg/dl | 4.8 (5-52.5) | 21.4 (4-74.8) | 4.9 (4-55.4) | 20.5 (4-83.9) | 0.016 |
| BMI         | 18.5-25 kg/m² | 22.8 (14.2-41.1) | 22.1 (17.7-33.7) | 23.8 (15.1-32.5) | 22.1 (18.7-28.1) | 0.839 |

With improvement of liver function, parameters of lipid metabolism were comparable between patients, independent of initial presentation.
differences were observed between different medical regimes. Thus, in our cohort we could not verify the previous observation of reduced cholesterol levels under zinc therapy [15,16].

In summary, our study at least in part contradicts the findings obtained in Wilson disease animal models. The most obvious alteration was a lower serum cholesterol level in hepatic- affected patients, which might be related to liver injury. Our data suggested an unpaired cholesterol metabolism in Wilson disease under therapy, regardless of the applied treatment regimen.

Material and methods

Patients
This cohort study involved 251 patients with an established diagnosis of Wilson disease examined at the University Hospitals of Heidelberg and Dresden between 1998 and 2009. The study protocol was a priori approved by the ethical committee of the University of Heidelberg.

The diagnosis of this disease was based on the criteria of the 8th International Conference of Wilson disease and Menkes disease [20]. Patients with uncertain diagnosis were excluded as described previously [21]. In terms of a cross sectional study, all patients were analysed on routine follow-up examinations for serum lipid profile, including triglycerides, cholesterol, HDL and LDL. Data on serum lipids at time of diagnosis were retrieved on routine follow-up examinations for serum lipid profile, including triglycerides, cholesterol, HDL and LDL. Data on serum lipids at time of diagnosis were retrieved by chart review and were not available for all cases. For statistical testing, they were subgrouped by treatment (d-penicillamine, trientine, zinc and combination), sex and manifestation (hepatic, neurological, mixed and asymptomatic). P-values were retrieved using Mann-Whitney or Kruskal-Wallis test.

Table 4 In patients subgrouped by different treatment regimens, no differences in lipid metabolism parameters were demonstrated, even under zinc monotherapy

|        | n  | Limits of normal | DPA       | Trientine | Zinc       | Combination | p-value |
|--------|----|------------------|-----------|-----------|------------|-------------|---------|
| ALT    | 249| f: -35 U/l m: -50 U/l | 36 (8-3743) | 30 (10-398) | 34.5 (14-162) | 34 (12-100) | 0.133   |
| AST    | 250| f: -35 U/l m: -50 U/l | 28 (11-2106) | 27 (12-167) | 25 (10-110) | 24 (12-79) | 0.775   |
| Bilirubin | 239| < 1.0 mg/dl | 0.7 (0.3-23) | 0.6 (0.2-4.5) | 0.6 (0.2-10) | 0.8 (0.3-1.8) | 0.306   |
| Albumin| 231| 30-50 g/l | 44.2 (28-54) | 43 (21-55) | 46 (24-73) | 44.4 (30-56) | 0.033   |
| TG     | 247| < 150 mg/dl | 106 (24-888) | 97 (29-287) | 94 (12-438) | 87 (44-178) | 0.505   |
| Cholesterol | 248| < 200 mg/dl | 179 (90-288) | 185.5 (107-365) | 187 (122-340) | 172 (137-259) | 0.780   |
| HDL    | 124| f: >50 mg/dl m: >40 mg/dl | 56 (27-103) | 59.5 (39-113) | 54 (39-100) | 48.5 (32-90) | 0.467   |
| LDL    | 115| < 160 mg/dl | 102.5 (43-204) | 98 (52-218) | 113 (51-229) | 94.5 (64-151) | 0.324   |
| BMI    | 166| 18.5-25 kg/m² | 23.7 (18.1-33.7) | 22.5 (14.2-41.1) | 21.9 (15.1-34.1) | 25.2 (18.5-29) | 0.060   |

Statistical methods

A p-value less than 0.05 was considered significant. Calculation was carried out using SPSS™ for Windows™ Software V15.0.

Abbreviations

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; Cp: ceruloplasmin; DPA: D-penicillamine; HDL: high-density lipoproteins; LEC: long evans chinnamon; LDL: low-density lipoproteins; LFT: liver function test; Lp(a): lipoprotein a; TG: triglycerides; VLDL: very low-density lipoproteins; WD: Wilson disease

Acknowledgements

We sincerely thank the patients for their help and willingness to participate in this study.

Author details

1Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany. 2Department of Neurology, University Hospital Dresden, Dresden, Germany.

Authors’ contributions

KHW, JS were involved in the study concept and design; acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the manuscript; study supervision; critical revision of the manuscript for important intellectual content/AG, NE were involved in the acquisition of data/DNG, JP, WS, UR were involved in the acquisition of data; critical revision of the manuscript for important intellectual content; statistical analysis.

All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 5 April 2011 Accepted: 19 May 2011 Published: 19 May 2011

References

1. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML: Wilson’s disease. Lancet 2007, 369(9559):397-408.

2. Ferenci P: Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 2004, 19(3-4):229-239.
3. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995, 9(2):210-217.

4. Cox DW, Moore SD. Cooper transporting P-type ATPases and human diseases. J Bioenerg Biomemb 2002, 34(5):333-338.

5. Ferenci P. Regional distribution of mutations of the ATB7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 2006, 120(2):151-159.

6. Stremmel W, Meyerrose KW, Niederau C, Hefter H, Kreuzpaintner G, Strohmeyer G. Wilson disease: clinical presentation, treatment and survival. Ann Intern Med 1991, 115(9):720-726.

7. Huster D. Wilson disease. Best Pract Res Clin Gastroenterol 2010, 24(5):531-539.

8. Ferenci P, Czlonkowska A, Merle U, Ference S, Gromadzka G, Yurdaydin C, Vogel W, Bruha R, Schmidt HT, Stremmel W. Late-onset Wilson’s disease. Gastroenterology 2007, 132(4):1294-1298.

9. Vergani C, Trovato G, Delu A, Pietrogrande M, Dioguardi N. Serum total lipids, lipoprotein cholesterol, and apolipoprotein A in acute viral hepatitis and chronic liver disease. J Clin Pathol 1998, 51(8):772-778.

10. Huster D, Purnat TD, Burkhead JL, Ralle M, Stuckert F, Olson NE, Teuper S, Lutsenko S. High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. J Biol Chem 2007, 282(11):8343-8355.

11. Levy E, Brunet S, Alvarez F, Seidman E, Bouchard G, Escobar E, Martin S. Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson’s disease. Life Science 2007, 80(16):1472-1483.

12. Yount QN, McNamara DJ, Al-Othman AA, Lei KY. The effect of copper deficiency on rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. J Nut Biochem 1990, 1(1):21-27.

13. Huster D, Lutsenko S. Wilson disease: not just a cooper disorder. Analysis of Wilson disease model demonstrates the link between cooper and lipid metabolism. Mol Bio Syst 2007, 3(1):186-824.

14. Galhardi CM, Diniz YS, Rodrigues HG, Faine LA, Bumeko RC, Ribas BO, Novelli EL. Beneficial effects of dietary copper supplementation on serum lipids and antioxidant defenses in rats. Ann Nutr Metab 2005, 49(5):283-288.

15. Brewer JG, Yuzbasiyan-Gurkan V, Johnson V. Treatment of Wilson’s disease with zinc IX: Response of serum lipids. J Lab Clin Med 1991, 118(5):466-470.

16. Rodo M, Czarnecki A, Pulawiska M, Swiderska M, Tarnacka B, Wehr H. The level of serum lipid, vitamin E and low density lipoprotein oxidation in Wilson’s disease patients. Europ J Neurol 2007, 4:491-494.

17. Hooper PL, Visconti L, Garry PJ, Johnson GE. Zinc lowers high-density lipoprotein-cholesterol levels. Jama 1980, 244(17):1960-1961.

18. Chandra RK. Excessive intake of zinc impairs immune responses. Jama 1984, 252(11):1443-1446.

19. Black WR, Medeiros D, Brunet E, Welke R. Zinc supplements and serum lipids in young adult white males. Am J Clin Nutr 1988, 47(6):970-975.

20. Ferencz C, Caca K, Loundianos G, Mieli-Vergani G, Tanner S, Steinleib I, Schilsky M, Cox D, Beri F. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003, 23(3):139-142.

21. Weiss KH, Gotthardt DN, Klemm D, Merle U, Ferenci-Forster D, Schaefer M, Ferenci P, Stremmel W. Zinc Monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011, 140(4):1189-1198.